In the abstract titled “Analgesia during long-term lubiprostone therapy in patients with opioid-induced constipation and chronic, non-cancer pain: results from a phase 3, open-label clinical trial” (Joswick et al, J Pain 14:S79, 2013) the following correction should be made: During the study, 24.6% of patients reported a treatment-related adverse event (AE), most commonly nausea and diarrhea (5.0% and 4.6%, respectively). No drug-related serious AEs were reported. Five (1.1%) and 5 (1.1%) patients withdrew because of nausea and diarrhea, respectively; 2 cases of nausea and 2 cases of diarrhea were severe. Reliance on rescue medication decreased from 33.0% to 18.6% of patients from months 1 to 9.

        Linked Article